<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00764361</url>
  </required_header>
  <id_info>
    <org_study_id>2008-DOX-NT/003</org_study_id>
    <nct_id>NCT00764361</nct_id>
  </id_info>
  <brief_title>Safety Study of Topical Doxycycline Gel for Adult Diabetic Lower Extremity Ulcers</brief_title>
  <official_title>A Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of NanoDOX™ Hydrogel(1.0% Doxycycline Monohydrate)in Diabetic Adult Subjects With Lower Extremity Ulcers Compared to Placebo Hydrogel.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NanoSHIFT LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NanoSHIFT LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a double-blind, one center, two-arm study with a two (2) week Run-In,
      evaluating the efficacy of a once-daily administration of NanoDOX™ Hydrogel topically applied
      to diabetic ulcers in concert with professionally administered Standard of Care (SOC)
      procedures as described by Standard Operating Procedure(s) of the Department of Veterans
      Administration Hospitals. During the run-in period patients with infected wounds will receive
      oral antibiotic and not be included in the topical portion of the study until the infection
      is shown by wound fluid analysis to be resolved. Following a two (2) week Run-In of all
      patients to receive SOC treatment for diabetic ulcers, patients would have either the
      investigational material or the placebo hydrogel applied as a part of their wound care. Each
      patient would receive 1.5 gm packets of either the test article or the placebo hydrogel for a
      once-daily home treatment accompanied by a dressing change.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study of NanoDOX vs placebo on diabetic ulcers of the lower leg/foot.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">August 2010</completion_date>
  <primary_completion_date type="Actual">August 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Without Adverse Events</measure>
    <time_frame>every 2 weeks</time_frame>
    <description>Participants were monitored for 20 weeks during the study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Analyze the Molecular Changes in Pro-inflammatory Cytokine Levels That Occur in Diabetic Foot Ulcers as a Function of Healing Rate in the Presence /Absence of NanoDOX Hydrogel (1% Doxycycline Monohydrate Gel)</measure>
    <time_frame>baseline, week 4, week 10, week 20</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Diabetic Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>NanoDOX™ Hydrogel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0% doxycycline gel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo gel</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxycycline</intervention_name>
    <description>1.0% doxycycline gel applied topically to the wound once daily for 20 weeks</description>
    <arm_group_label>NanoDOX™ Hydrogel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo gel</intervention_name>
    <description>placebo gel applied topically to the wound once daily for 20 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>doxycycline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a documented history of type I or type II diabetes mellitus as defined by the
             American Diabetes Association

          -  Women of childbearing potential must have a negative urine pregnancy test at screening
             and at baseline, and:

             • Agree to use a double-barrier method of contraception during their participation in
             this study;

               -  condoms (with spermicide) and hormonal contraceptives OR

               -  condoms (with spermicide) and intrauterine device OR

               -  intrauterine device and hormonal contraceptives OR

               -  Abstains from sexual intercourse during their participation in this study OR

               -  Is with a same-sex partner and does not participate in bisexual activities where
                  there is a risk of becoming pregnant

          -  Have an ulcer on the lower extremity (distal to a line connecting the medial and
             lateral malleoli) that has been present for at least 3 weeks and that is 1.2 cm2 to
             4.0 cm2 at initial screening

          -  Be able to apply study drug to their ulcer, or have a caregiver do it

          -  Adequate blood flow to target ulcer extremity as measured by transcutaneous oxygen
             tension (TcpO2) of &gt;30mmHg

          -  Target ulcer is Grade I according to the Wagner Grading Scale

          -  Quantitative bacterial count of of &lt; 1.0 x 1.0E5 per gram of tissue for non-infected
             ulcers

          -  Quantitative bacterial count of ≥ 1.0 x 1.0E5 per gram of tissue for infected ulcers

        Exclusion Criteria:

          -  Be a pregnant or lactating woman or a female of childbearing potential who is not
             practicing acceptable form of birth control.

          -  Allergy to tetracycline, minocycline, demeclocycline, or any other known tetracycline
             derivative

          -  Have more than three chronic ulcers present at baseline

          -  Have undergone treatment with system corticosteroid or immunosuppressive therapy in
             the past 2 months

          -  Have connective tissue disease

          -  Currently be going through kidney dialysis for renal failure

          -  Have undergone treatment with doxycycline, Procuren®, or Regranex® within the last 30
             days

          -  Have participated in another clinical research trial within the last 30 days

          -  Have a known history of osteomyelitis affecting to the area where the target ulcer is
             present

          -  Have any other concomitant condition which, in the opinion of the investigator, would
             make the subject unsuitable for the study.

          -  Subject has ulcers resulting from any cause other than diabetes (electrical burn,
             arterial insufficiency, chemical or radiation insult)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Abernethy, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ology Bioservices</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>North Florida / South Georgia Veterans Administration Hospital</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 1, 2008</study_first_submitted>
  <study_first_submitted_qc>October 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 2, 2008</study_first_posted>
  <results_first_submitted>February 24, 2012</results_first_submitted>
  <results_first_submitted_qc>March 8, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 5, 2012</results_first_posted>
  <last_update_submitted>March 9, 2017</last_update_submitted>
  <last_update_submitted_qc>March 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Diabetic</keyword>
  <keyword>Ulcer</keyword>
  <keyword>Wound</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Diabetic Foot</mesh_term>
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Leg Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>subjects were recruited through the local veterans administration clinics</recruitment_details>
      <pre_assignment_details>adult subjects with diabetic lower extremity ulcers were enrolled into the study after determination that the wound was not infected</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>NanoDOX™ Hydrogel</title>
          <description>1.0% doxycycline gel</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>NanoDOX™ Hydrogel</title>
          <description>1.0% doxycycline gel</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo gel</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="7"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.99" spread="11.53"/>
                    <measurement group_id="B2" value="68.86" spread="9.75"/>
                    <measurement group_id="B3" value="66.33" spread="10.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Without Adverse Events</title>
        <description>Participants were monitored for 20 weeks during the study.</description>
        <time_frame>every 2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>NanoDOX™ Hydrogel</title>
            <description>1.0% doxycycline monohydrate gel</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Without Adverse Events</title>
          <description>Participants were monitored for 20 weeks during the study.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Analyze the Molecular Changes in Pro-inflammatory Cytokine Levels That Occur in Diabetic Foot Ulcers as a Function of Healing Rate in the Presence /Absence of NanoDOX Hydrogel (1% Doxycycline Monohydrate Gel)</title>
        <time_frame>baseline, week 4, week 10, week 20</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>NanoDOX™ Hydrogel</title>
          <description>1.0% doxycycline gel</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo gel</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>enrollment stopped before reaching the initial 40 subjects anticipated due to slow enrollment of subjects</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>John Abernethy, MD - Medical Director</name_or_title>
      <organization>Nanotherapeutics, Inc.</organization>
      <phone>386-462-9663 ext 326</phone>
      <email>jabernethy@nanotherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

